BioCardia, Inc. Signs Merger Agreement with Tiger X Medical, Inc., Secures Funding to Support Further Development of CardiAMP® Cell Therapy System for the Treatment of Heart Failure
August 22, 2016
SAN CARLOS, CA –BioCardia, Inc., a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases, announced today that it has entered into a definitive agreement to merge with Tiger X Medical, Inc. (OTCQB: CDOM). The combined entity, which will change its name to BioCardia following the closing, will trade on the OTC Markets and will focus solely on the business of BioCardia.
The combined entity is expected to have $23 million in cash at closing, which will be used to support the ongoing Phase III Heart Failure Trial, for the commercialization and development of other product candidates, and for general corporate purposes. OPKO Health Inc. (OPK, NYSE) will become a significant stockholder in Tiger X Medical and will also serve as an advisor to the business.
“Our CardiAMP cell therapy is seeking to address an enormous unmet need – a treatment for heart failure that develops after a patient has had a heart attack. The merger will provide resources necessary to continue our Phase III development of CardiAMP.” said Dr. Peter Altman, BioCardia’s CEO.
BioCardia is commencing a Phase III study of its CardiAMP cell therapy system for the treatment of heart failure. The Food and Drug Administration (FDA) has approved the study under an Investigational Device Exemption (IDE). The Centers for Medicaid and Medicare Services (CMS) have approved this IDE Nationally as qualified for CMS reimbursement.
The CardiAMP cell therapy for heart failure integrates a proprietary biomarker panel to identify candidates likely to respond to therapy, a cell processing system which prepares a proprietary, high-dosage formulation of autologous bone marrow-derived cells and a unique transendocardial delivery system that ensures efficient and consistent targeted delivery.
The CardiAMP clinical trial is a randomized, controlled, multi-center study of 250 patients evaluating CardiAMP Therapy at up to 40 clinical sites in the United States. It follows two previous clinical studies sponsored by BioCardia supporting the CardiAMP Therapy. Additional details are available via ClinicalTrials.gov, using identifier: NCT02438306.
Results from the trial will be reviewed under the PMA regulations by the FDA’s Center for Biologics Evaluation and Research (CBER) division.
BioCardia, Inc., headquartered in San Carlos, CA, is a privately-held company developing regenerative biologic therapies to treat cardiovascular disease. The Company's current products include the Helix™ transendocardial delivery system and the Morph® steerable guide and sheath catheter portfolio. CardiAMP® and CardiALLO® cell therapies are the company’s biotherapeutic product candidates in clinical development. BioCardia also partners with other biotherapeutic companies to provide its Helix systems and clinical support to their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia and acute myocardial infarction.
Forward Looking Statements:
This press release contains forward-looking statements. Such forward-looking statements include, among other things, references to anticipated cash balance, use of funds and product development plans. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies, unexpected expenditures, the ability to raise the additional funding needed to continue to pursue BioCardia’s business and product development plans, competition in the industry in which BioCardia operates and overall market conditions, whether OPKO Health becomes a significant stockholder of Tiger X Medical, and whether the merger between BioCardia and Tiger X Medical will close. These forward-looking statements are made as of the date of this press release, and BioCardia and Tiger X Medical assume no obligation to update the forward-looking statements.
Investors and Media:
David McClung, Vice President Finance & CFO
For Tiger X Medical:
Steve Rubin, Interim CEO
Henry Ford Health System
Cell & Gene
The Big Biz show
CALL US NOW
EMAIL US NOW